Furthermore, the observed relationship between RSPRY1 deficiency and TGF-β signaling might provide a foundation for novel targeted therapeutic strategies for patients with SEMD and other related skeletal dysplasias. Here, TGFB1 is linked to spondyloepimetaphyseal dysplasia.